Societal CDMO, Inc. announced that it has been selected by Spinnaker Biosciences, Inc., to execute CDMO services in support of the companyâs clinical development of a novel therapeutic candidate. The activities to be conducted under the agreement include analytical method transfer and qualification, aseptic process development, manufacture of a prototype batch of the therapeutic, cGMP filling of the resultant sterile powder into vials, and stability testing of the therapeutic candidate to be used in a planned Phase 1/2 study.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.1 USD | +0.92% | -.--% | +213.84% |
04-08 | Societal CDMO, Inc. Announces Board and Committee Resignations | CI |
04-08 | Societal CDMO, Inc.(NasdaqCM:SCTL) dropped from NASDAQ Composite Index | CI |
1st Jan change | Capi. | |
---|---|---|
+213.84% | 116M | |
+37.88% | 705B | |
+32.82% | 583B | |
-3.63% | 364B | |
+20.23% | 332B | |
+4.94% | 291B | |
+16.64% | 238B | |
-4.13% | 210B | |
+10.63% | 209B | |
+8.77% | 169B |
- Stock Market
- Equities
- SCTL Stock
- News Societal CDMO, Inc.
- Spinnaker Biosciences Selects Societal CDMO to Provide CDMO Services to Support Clinical Development of Novel Therapeutic Candidate